WuXi PharmaTech leads, Schrodinger completes $85 million in Series E financing
Recently, the arterial network learned through foreign media that biotechnology research company Schrodinger announced the completion of the $85 million E round of financing to support the continued growth and innovation of its computing platform, as well as expand its drug discovery channels. Founded in 1990, Schrodinger is a leading provider of advanced molecular simulation and enterprise software solutions. It is a leader in life sciences and materials research, revolutionizing drug discovery through advanced molecular simulation technology. The company's mission is to improve human health and quality of life by developing, distributing and applying advanced computing methods. This round of financing was led by the Bill and Melinda Gates Foundation Trust and the Wuxi WuXi PharmaTech Venture Capital Fund, leading life science and technology investors Deerfield Management, Baron, Qiming Ventures, GV (formerly Google Ventures) participated. “Schrodinger has proven that accurate molecular design can significantly accelerate drug discovery and bring unexpected solutions that benefit patients. We are very willing to support Schrodinger in this stage of development,†said Bill Gates, who has been since 2010. He has led three investments in Schrodinger. This new investment will support Schrodinger's ongoing development research to expand its widely used computing platform for drug discovery and materials research. The company also plans to increase its scientists and developers and expand its drug development team to develop a growing asset pipeline. Schrodinger's product line covers collaborative projects and patent programs for a variety of indications, including several compounds in clinical development. Li Ge, Chairman and CEO of Wuxi WuXi PharmaTech Group, said: “We are impressed by Schrodinger's ability to promote new drug development in an innovative way. We expect this investment to bring faster treatment to patients with severe diseases. Progress." “This investment will enable us to continue to advance our technology platform and help our users accelerate their work in life sciences and materials design. We are also excited to expand our drug development work and use our platform to expand our The product line is more effective in developing new drugs," said Dr. Ramy Farid, CEO of Schrodinger. "Our growth will help us achieve our mission to improve human health and quality of life." Our mission: To protect the health of ear, throat and nose with medical frontier knowledge and technological innovation. Migraine Reliever, Head Massager, Eye Massager, Neck Massager Ningbo Jiamai Internet Technology CO., Ltd. , https://www.jmcuhyd.com
Our vision: Leader in several niche markets of Otolaryngology.
Our values: Change, Enterprising, Share